Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Hsp90: still a viable target in prostate cancer|
|Citation:||Biochimica et Biophysica Acta-Reviews on Cancer, 2013; 1835(2):211-218|
|Publisher:||Elsevier Science BV|
|Margaret M. Centenera, Alyssa K. Fitzpatrick, Wayne D. Tilley, Lisa M. Butler|
|Abstract:||Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the maturation, activation and stability of critical signaling proteins that drive the development and progression of prostate cancer, including the androgen receptor. Despite robust preclinical data demonstrating anti-tumor activity of first-generation Hsp90 inhibitors in prostate cancer, poor clinical responses initially cast doubt over the clinical utility of this class of agent. Recent advances in compound design and development, use of novel preclinical models and further biological insights into Hsp90 structure and function have now stimulated a resurgence in enthusiasm for these drugs as a therapeutic option. This review highlights how the development of new-generation Hsp90 inhibitors with improved physical and pharmacological properties is unfolding, and discusses the potential contexts for their use either as single agents or in combination, for men with metastatic prostate cancer.|
|Keywords:||Hsp90; Inhibitors; Prostate cancer; Clinical trials|
|Rights:||Copyright © 2013 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.